Implantica AG (STU:8IM1)

Q1 2025 Implantica AG Earnings Call Transcript

May 9, 2025 / 01:00 PM GMT

Release Date Price: €2.46 (-1.80%)

Transcript

Key Points

Positve

Implantica AG (FRA:8IM1) reported a 25% increase in net sales for Q1 2025 compared to the same period last year, driven by new centers and higher activity levels.
The company achieved an impressive adjusted gross margin of 97% for the quarter, up from 92% in the same period last year.
Implantica AG (FRA:8IM1) has a strong patent portfolio, with patents extending until 2044 in the US, providing a solid foundation for future growth.
The company has received positive feedback from the FDA on its clinical module, with only minor questions, indicating a promising path towards US market approval.
Implantica AG (FRA:8IM1) has identified over 100 surgeons interested in using its RefluxStop product post-US approval, highlighting strong market interest.

Negative

Despite the increase in sales, Implantica AG (FRA:8IM1) reported an operating loss of €4.2 million for the quarter, although this was a decrease from the previous year.
The company faces challenges in Europe, where reimbursement systems vary by country, impacting the ability to scale sales effectively.
Implantica AG (FRA:8IM1) is currently focusing resources on the US launch, which has delayed the mass production of its eHealth platform.
The company is still awaiting a decision from NICE in the UK, which could impact its ability to operate within the NHS system.
There is uncertainty regarding the exact timing of FDA approval for RefluxStop, which could affect the company's US market entry timeline.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

IMPsdba.ST - Implantica AG
Q1 2025 Implantica AG Earnings Call
May 09, 2025 / 01:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
The Ilantica Q1 2025 report presentation. For the first part of the presentation, the participants will be in listen-only mode. During the questions and answer session. Participants are able to ask questions by dialing und key 5 on their telephone keypad. Now I will hand the conference over to the speakers CEO Peter Forsl, CFO Andreas Ornberg, and Chief Corporate Affairs Officer Nicole Pearson. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Hello everybody. My name is Peter oucher, and welcome to the Q1 2025 presentation.

So myself, I have invested incredible lots

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.